The Goldman Sachs Group Lowers Celldex Therapeutics (NASDAQ:CLDX) Price Target to $31.00
Celldex Therapeutics (NASDAQ:CLDX – Free Report) had its price target decreased by The Goldman Sachs Group from $36.00 to $31.00 in a research report sent to investors on Friday,Benzinga reports. The Goldman Sachs Group currently has a neutral rating on the biopharmaceutical company’s stock. A number of other analysts have also commented on the company. […]
Celldex Therapeutics (NASDAQ:CLDX – Free Report) had its price target decreased by The Goldman Sachs Group from $36.00 to $31.00 in a research report sent to investors on Friday,Benzinga reports. The Goldman Sachs Group currently has a neutral rating on the biopharmaceutical company’s stock. A number of other analysts have also commented on the company. […]
